Facebook
Twitter
Telegram
Report an ErrorChemoCentryx Balance Sheet 2011-2024 | CCXI
Annual Balance Sheet ChemoCentryx
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-42.5 M | -7.9 M | 114 M | 140 M | 51.9 M | -12 M | -12.8 M | -16.1 M | -9.93 M | -7.56 M | 19.7 M |
Long Term Debt |
4.72 M | 18.1 M | 19.8 M | 19.7 M | 4.68 M | - | - | - | - | - | 10.5 M |
Long Term Debt Current |
2.81 M | 6.3 M | 1.5 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | 81.7 M | 84 M | 104 M | 77.1 M | 67.6 M | 154 K | 185 K | 242 K | 677 K | 16.2 M |
Total Current Liabilities |
63 M | 51.6 M | 59.1 M | 64.4 M | 32.9 M | 38.3 M | 5.49 M | 8.19 M | 6.87 M | 11.3 M | - |
Total Liabilities |
140 M | 133 M | 143 M | 169 M | 110 M | 106 M | 5.65 M | 8.38 M | 7.11 M | 12 M | 25.6 M |
Deferred Revenue |
11 M | 12.6 M | 37.7 M | 50.5 M | 23 M | 29 M | - | - | - | 3.76 M | 3.63 M |
Retained Earnings |
-617 M | -485 M | -430 M | -374 M | -289 M | -307 M | -267 M | -220 M | -173 M | -134 M | -94.3 M |
Total Assets |
426 M | 519 M | 209 M | 183 M | 189 M | 156 M | 78.2 M | 117 M | 152 M | 122 M | 102 M |
Cash and Cash Equivalents |
50 M | 32.3 M | 39.2 M | 28.1 M | 40 M | 12 M | 12.8 M | 16.1 M | 10.3 M | 8.46 M | 40.2 M |
Book Value |
286 M | 386 M | 66 M | 14.7 M | 79.3 M | 49.9 M | 72.5 M | 109 M | 145 M | 110 M | 76 M |
Total Shareholders Equity |
286 M | 386 M | 66 M | 14.7 M | 79.3 M | 49.9 M | 72.5 M | 109 M | 145 M | 110 M | 76 M |
All numbers in USD currency
Quarterly Balance Sheet ChemoCentryx
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | 4 M | 4.55 M | 4.72 M | 9.56 M | 11.6 M | 14.9 M | 18.1 M | 18.1 M | 18.1 M | 18.1 M | 19.8 M | 19.8 M | 19.8 M | 19.8 M | 19.7 M | 19.7 M | 19.7 M | 19.7 M | 4.68 M | 4.68 M | 4.68 M | 4.68 M | - | - | - | - | - | - | - | - | - | - | - | - | 16 K | - | - | - | 379 K | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | - | 183 M | 182 M | 140 M | 139 M | 137 M | 138 M | 133 M | 133 M | 133 M | 133 M | 143 M | 143 M | 143 M | 143 M | 169 M | 169 M | 169 M | 169 M | 110 M | 110 M | 110 M | 110 M | 106 M | 106 M | 106 M | 106 M | 5.65 M | 5.65 M | 5.65 M | 5.65 M | 8.38 M | 8.38 M | 8.38 M | 8.38 M | 7.11 M | 7.11 M | 7.11 M | 7.11 M | 12 M | 12 M | 12 M | 12 M | 25.6 M | 25.6 M | 25.6 M | 25.6 M |
Deferred Revenue |
- | - | 21 M | 18.7 M | 11 M | 15.6 M | 10.6 M | 13 M | 12.6 M | 12.6 M | 12.6 M | 12.6 M | 37.7 M | 37.7 M | 37.7 M | 37.7 M | 50.5 M | 50.5 M | 50.5 M | 50.5 M | 23 M | 23 M | 23 M | 23 M | 29 M | 29 M | 29 M | 29 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
- | - | -687 M | -656 M | -617 M | -577 M | -554 M | -515 M | -485 M | -485 M | -485 M | -485 M | -430 M | -430 M | -430 M | -430 M | -374 M | -374 M | -374 M | -374 M | -289 M | -289 M | -289 M | -289 M | -307 M | -307 M | -307 M | -307 M | -267 M | -267 M | -267 M | -267 M | -220 M | -220 M | -220 M | -220 M | -173 M | -173 M | -173 M | -173 M | -134 M | -134 M | -134 M | -134 M | -94.3 M | -94.3 M | -94.3 M | -94.3 M |
Total Assets |
- | - | 419 M | 440 M | 426 M | 455 M | 468 M | 499 M | 519 M | 519 M | 519 M | 519 M | 209 M | 209 M | 209 M | 209 M | 183 M | 183 M | 183 M | 183 M | 189 M | 189 M | 189 M | 189 M | 156 M | 156 M | 156 M | 156 M | 78.2 M | 78.2 M | 78.2 M | 78.2 M | 117 M | 117 M | 117 M | 117 M | 152 M | 152 M | 152 M | 152 M | 122 M | 122 M | 122 M | 122 M | 102 M | 102 M | 102 M | 102 M |
Cash and Cash Equivalents |
- | - | 44.4 M | 40.6 M | 50 M | 93.7 M | 78.3 M | 68.5 M | 33.4 M | 32.3 M | 32.3 M | 32.3 M | 39.2 M | 39.2 M | 39.2 M | 39.2 M | 28.1 M | 28.1 M | 28.1 M | 28.1 M | 40 M | 40 M | 40 M | 40 M | 12 M | 12 M | 12 M | 12 M | 12.8 M | 12.8 M | 12.8 M | 12.8 M | 16.1 M | 16.1 M | 16.1 M | 16.1 M | 10.3 M | 10.3 M | 10.3 M | 10.3 M | 8.46 M | 8.46 M | 8.46 M | 8.46 M | 40.2 M | 40.2 M | 40.2 M | 40.2 M |
Book Value |
- | - | 237 M | 259 M | 286 M | 316 M | 330 M | 361 M | 386 M | 386 M | 386 M | 386 M | 66 M | 66 M | 66 M | 66 M | 14.7 M | 14.7 M | 14.7 M | 14.7 M | 79.3 M | 79.3 M | 79.3 M | 79.3 M | 49.9 M | 49.9 M | 49.9 M | 49.9 M | 72.5 M | 72.5 M | 72.5 M | 72.5 M | 109 M | 109 M | 109 M | 109 M | 145 M | 145 M | 145 M | 145 M | 110 M | 110 M | 110 M | 110 M | 76 M | 76 M | 76 M | 76 M |
Total Shareholders Equity |
- | - | 237 M | 259 M | 286 M | 316 M | 330 M | 361 M | 386 M | 386 M | 386 M | 386 M | 66 M | 66 M | 66 M | 66 M | 14.7 M | 14.7 M | 14.7 M | 14.7 M | 79.3 M | 79.3 M | 79.3 M | 79.3 M | 49.9 M | 49.9 M | 49.9 M | 49.9 M | 72.5 M | 72.5 M | 72.5 M | 72.5 M | 109 M | 109 M | 109 M | 109 M | 145 M | 145 M | 145 M | 145 M | 110 M | 110 M | 110 M | 110 M | 76 M | 76 M | 76 M | 76 M |
All numbers in USD currency